BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters

BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters

Objective: To investigate the association of the BRAFV600E mutation with papillary thyroid carcinoma using clinical, morphological and prognostic parameters. We also intend to assess the utility of the BRAFV600E immunohistochemistry and compare it with BRAF polymerase chain reaction (RT-PCR). Materi...

Full description

Bibliographic Details
Main Authors:	Faruk Erdem KOMBAK, Naziye ÖZKAN, Mustafa Ümit UĞURLU, Handan KAYA
Format:	Article
Language:	English
Published:	Federation of Turkish Pathology Societies 2019-05-01
Series:	Türk Patoloji Dergisi
Subjects:	Thyroid Papillary carcinoma BRAFV600E Immunohistochemistry Reverse Transcriptase PCR Prognosis
Online Access:	http://www.turkjpath.org/pdf.php3?id=1885

Similar Items

Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules
by: Tatiana Marina Vieira Giorgenon, et al.
Published: (2019-03-01)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
by: Yan-Yu Lin, et al.
Published: (2023-01-01)

Clinicopathological Implications of the BRAFV600E Mutation in Papillary Thyroid Carcinoma of Ukrainian Patients Exposed to the Chernobyl Radiation in Childhood: A Study for 30 Years After the Accident
by: Liudmyla Zurnadzhy, et al.
Published: (2022-04-01)

Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma
by: Qing Zhang, et al.
Published: (2016-02-01)

IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
by: Muhammad Umer Ch, et al.
Published: (2021-10-01)

Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
by: Xiaoquan Hong, et al.
Published: (2024-01-01)

Association between BRAFV600E mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients
by: Havva Sezer, et al.
Published: (2020-08-01)

BRAFV600E mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
by: Nada M. Yakout, et al.
Published: (2023-02-01)

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
by: Dong Chen, et al.
Published: (2023-01-01)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
by: Shuhui Huang, et al.
Published: (2022-11-01)

T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma
by: Xubin Dong, et al.
Published: (2020-12-01)

X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
by: Sandeep Kumar Parvathareddy, et al.
Published: (2022-12-01)

Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy
by: Kirk Jensen, et al.
Published: (2020-08-01)

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
by: Harahap AS, et al.
Published: (2023-05-01)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
by: Raffaella De Paolo, et al.
Published: (2023-07-01)

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy
by: Guoquan Zhu, et al.
Published: (2019-05-01)

BRAFV600E mutation and DSS treatment synergize to induce cecal tumor formation in mice
by: Chenxi Gao, et al.
Published: (2024-03-01)

Integrating BRAFV600E mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma
by: Zheng Zhang, et al.
Published: (2022-04-01)

BRAFV600E Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT
by: Yuan Gao, et al.
Published: (2022-05-01)

Major Vault Protein (MVP) Associated With BRAFV600E Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways
by: Xubin Dong, et al.
Published: (2022-03-01)

Glioblastoma with BRAFV600E mutation and numerous metastatic foci: a case report
by: Karolina Janik, et al.
Published: (2019-03-01)

Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
by: Qianqian Xu, et al.
Published: (2024-06-01)

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules
by: Huang G, et al.
Published: (2023-12-01)

AI‐BRAFV600E: A deep convolutional neural network for BRAFV600E mutation status prediction of thyroid nodules using ultrasound images
by: Chuang Xi, et al.
Published: (2023-04-01)

Immunohistochemical Detection of BRAFV600E in Cutaneous Melanocytic Neoplasms in a Cohort of Egyptian Population
by: Nada M. Yakout, et al.
Published: (2022-12-01)

Profile and clinical implication of circular RNAs in human papillary thyroid carcinoma
by: Huihui Ren, et al.
Published: (2018-08-01)

Rethinking the role of oncogenes in papillary thyroid cancer initiation
by: Mario eVitale
Published: (2012-06-01)

Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot
by: Eimei Iwama, et al.
Published: (2015-10-01)

Clinical outcome, role of BRAFV600E, and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?
by: Carmelo eNucera, et al.
Published: (2012-02-01)

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
by: Yasemin Giles Şenyürek, et al.
Published: (2022-06-01)

Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer
by: Jingran Ji, et al.
Published: (2023-01-01)

Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence
by: Taciana Padilha de Castro, et al.
Published: (2019-12-01)

Relationship of the recurrence after pterygium surgery with the presence of HSV, EBV, CMV, HPV, and BRAFV600E mutation
by: S.O. Rykov, et al.
Published: (2019-02-01)

Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1H-pyrazole as highly selective and potent BRAFV600E and CRAF inhibitor
by: Jinwoong Kim, et al.
Published: (2019-01-01)

Melanoma-Derived BRAFV600E Mutation in Peritumoral Stromal Cells: Implications for in Vivo Cell Fusion
by: Zsuzsanna Kurgyis, et al.
Published: (2016-06-01)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
by: Iris Car, et al.
Published: (2023-04-01)

Indolent renal involvement with BRAFV600E mutation: Erdheim‐Chester, a rare disease with a wide spectrum of clinical manifestations
by: Charlotte Vanhomwegen, et al.
Published: (2021-08-01)

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
by: Noha Mukhtar, et al.
Published: (2023-10-01)

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
by: Iris Car, et al.
Published: (2023-08-01)

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations
by: Yanjun Su, et al.
Published: (2021-03-01)